Bayesian designs of phase II oncology trials to select maximum effective dose assuming monotonic dose-response relationship

BACKGROUND: For many molecularly targeted agents, the probability of response may be assumed to either increase or increase and then plateau in the tested dose range. Therefore, identifying the maximum effective dose, defined as the lowest dose that achieves a pre-specified target response and beyon...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Beibei, Li, Yisheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4119476/
https://www.ncbi.nlm.nih.gov/pubmed/25074481
http://dx.doi.org/10.1186/1471-2288-14-95

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4119476/
https://www.ncbi.nlm.nih.gov/pubmed/25074481
http://dx.doi.org/10.1186/1471-2288-14-95

Ejemplares similares